OnKure Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision medicines that target biologically validated drivers of cancers. Its lead product candidate includes OKI-219, a selective inhibitor of phosphoinositide 3 kinase alpha harboring the H1047R mutation that is in Phase 1 clinical trial for the treatment of solid tumors, including breast cancer. The company is headquartered in Boulder, Colorado. Show more

Location: 6707 Winchester Circle, Boulder, CO, 80301, United States | Website: https://onkuretherapeutics.com | Industry: Biotechnology | Sector: Healthcare


Market Cap

37.61M

52 Wk Range

$1.70 - $19.40

Previous Close

$2.88

Open

$2.77

Volume

90,976

Day Range

$2.72 - $2.95

Enterprise Value

-44.67M

Cash

83.37M

Avg Qtr Burn

-15.32M

Insider Ownership

1.73%

Institutional Own.

87.14%

Qtr Updated

06/30/25


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.